Abstract: Aspects of the present disclosure relate to systems and methods for sorting one or more files hosted by a collaborative application. In one aspect, one or more activity signals associated with one or more files hosted by the collaborative application may be received from a substrate. An activity-based sort order may be determined using at least a combination of the one or more activity signals. The activity-based sort order may be applied to sort the one or more files hosted by the collaborative application for display in a user interface to an activity object of the collaborative application.

Abstract: Systems and methods are provided herein for creating and building a model of a unique infrastructure, such as a parking structure. The model may be created through the identification of various triggers by a vehicle traversing the infrastructure. The triggers may include, for example, sensors or other devices capable of sensing the vehicle within the infrastructure. The triggers may also be information received from the vehicle itself. Based on the triggers, it may be inferred that various places exist throughout the infrastructure. For example, it may be inferred through two subsequent triggers that a place exists between the two triggers. The place may be added to the model of the infrastructure in between the two triggers. The model may continue to grow in this manner.

Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

Abstract: In a method for substantially isolating cardiac circulation from systemic circulation, flow between the coronary sinus and the right atrium is occluded. A venous collection device having a collection lumen and a support structure is located in the coronary sinus. The support structure is used to maintain patency of the coronary sinus during collection of fluid through the collection lumen. An artificial flow path is provided between the collection lumen and the one or more coronary arteries, thus isolating the cardiac circulation. According to the method, cardiac pumping for systemic circulation can be maintained during isolation of the cardiac circulation.

Abstract: A method for treating an occlusion in a coronary artery of a patient includes percutaneously advancing an occlusion treatment tool (such as an angioplasty balloon or stent delivery device) through the vasculature of the patient and into a coronary artery to a site of the occlusion. Following the treatment of the occlusion, a therapeutic agent is admitted into the first coronary artery. The therapeutic agent is selected to treat microvasculature obstructions at a target cardiac tissue site distal to the site of the occlusion.

Abstract: An air purification system includes an electrostatic collection grid module inside the housing of the system to remove particulate matter from the air flowing through the housing. The collection grid module is removable from a side of the housing. The collection grid module is equipped with a handle and a release mechanism. A user may draw out the collection grid module from the housing by pulling the handle while activating the release mechanism. Thus, the collection grid module may be cleaned with ease.

Abstract: A method for delivering a polynucleotide to cardiac tissue, including substantially isolating the coronary venous circulation from systemic circulation, and introducing a polynucleotide into the isolated coronary venous circulation to effect localized transfection of cardiac tissue. The polynucleotide advantageously produces a therapeutic effect, such as increasing or decreasing the expression level of a protein in the cardiac tissue.

Abstract: In the present specification we describe a new class of compounds, designed to modulate the ability of blood vessels to synthesize NO from L-arginine. In particular we have identified novel compounds which enhance the entry of L-arginine into cells. These compounds improve endothelial function, and thereby have the potential to retard the progression of vascular disease in conditions such as hypertension, heart failure and diabetes. This new class of drugs may also have other potentially, relevant pharmacological actions, including anti-hypertensive and anti-anginal actions.

Abstract: Disclosed are a system, device, and method for controlling a differential fluid pressure between chambers in a heart. The device includes an implantable pop-off valve that may be secured between two chambers of a heart, such as the left and right atriums. The pop-off valve is normally in a closed position. If a differential fluid pressure across the device exceeds a pre-determined value, the pop-off valve is arranged to open to enable blood flow between the two chambers of the heart. When it is determined that the differential fluid pressure is substantially below the pre-determined value, the pop-off valve is configured to close. The system and method further discloses means for implanting the device into a septal region of the heart.